Clinical Trials Browser

Phase 1/2 × eprenetapopt × Gastrointestinal × Clear all

NCT04383938 2025-05-13

Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies

Phase 1/2 Completed

40 enrolled 11 charts

GastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms